{"doi":"10.1093/infdis/jiaa507","title":"Methods of Inactivation of SARS-CoV-2 for Downstream Biological Assays","abstract":"The scientific community has responded to the coronavirus disease 2019 (COVID-19) pandemic by rapidly undertaking research to find effective strategies to reduce the burden of this disease. Encouragingly, researchers from a diverse array of fields are collectively working towards this goal. Research with infectious severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is undertaken in high-containment laboratories; however, it is often desirable to work with samples at lower-containment levels. To facilitate the transfer of infectious samples from high-containment laboratories, we have tested methods commonly used to inactivate virus and prepare the sample for additional experiments. Incubation at 80°C, a range of detergents, Trizol reagents, and UV energies were successful at inactivating a high titer of SARS-CoV-2. Methanol and paraformaldehyde incubation of infected cells also inactivated the virus. These protocols can provide a framework for in-house inactivation of SARS-CoV-2 in other laboratories, ensuring the safe use of samples in lower-containment levels.","journal":"The Journal of Infectious Diseases","year":2020,"id":49390,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":261,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9609,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2020-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":230611,"name":"Tessa Prince","orcid":"0000-0002-8796-2629","position":1,"is_corresponding":false},{"id":230610,"name":"Enyia R. Anderson","orcid":"0000-0002-8764-6706","position":2,"is_corresponding":false},{"id":237821,"name":"Aitor Casas-Sánchez","orcid":"0000-0001-5237-1223","position":3,"is_corresponding":false},{"id":237822,"name":"Shirley L. Smith","orcid":"0000-0003-1287-4277","position":4,"is_corresponding":false},{"id":237823,"name":"Cintia Cansado-Utrilla","orcid":"0000-0001-6272-4782","position":5,"is_corresponding":false},{"id":83868,"name":"Tom Solomon","orcid":"0000-0001-7266-6547","position":6,"is_corresponding":false},{"id":237824,"name":"Michael J. Griffiths","orcid":"0000-0003-1851-6155","position":7,"is_corresponding":false},{"id":237825,"name":"Álvaro Acosta-Serrano","orcid":"0000-0002-2576-7959","position":8,"is_corresponding":false},{"id":81314,"name":"Lance Turtle","orcid":"0000-0002-0778-1693","position":9,"is_corresponding":false},{"id":230622,"name":"Grant L. Hughes","orcid":"0000-0002-7567-7185","position":10,"is_corresponding":false},{"id":230605,"name":"Edward I. Patterson","orcid":"0000-0003-3465-0848","position":0,"is_corresponding":true}],"reference_count":28,"raw_metadata":null,"created_at":"2026-07-18T20:36:25.163232Z","pmid":"32798217","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}